PubRank

Sven Perner

Author PubWeight™ 195.26‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005 39.06
2 Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007 18.83
3 Characterizing the cancer genome in lung adenocarcinoma. Nature 2007 16.48
4 SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009 7.48
5 Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010 6.39
6 Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012 5.28
7 Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008 3.55
8 Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011 3.43
9 Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer 2009 3.03
10 Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009 2.94
11 The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008 2.87
12 Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008 2.58
13 Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009 2.51
14 Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 2009 2.47
15 Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010 2.40
16 TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007 2.28
17 Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (RCC). BJU Int 2013 2.10
18 An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol 2014 1.95
19 An oncogenic role for ETV1 in melanoma. Cancer Res 2010 1.94
20 Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med 2009 1.79
21 Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate 2010 1.78
22 Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 2007 1.75
23 Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer 2011 1.74
24 N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009 1.68
25 Prognostic factors in lymph node-positive prostate cancer. Urology 2006 1.66
26 SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 2011 1.66
27 ERG rearrangement in small cell prostatic and lung cancer. Histopathology 2010 1.64
28 Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology 2009 1.56
29 Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 2010 1.55
30 Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol 2012 1.50
31 Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013 1.49
32 mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 2011 1.40
33 SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum Pathol 2011 1.40
34 SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res 2013 1.34
35 ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010 1.33
36 Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006 1.33
37 A fatal case of necrotizing sinusitis due to toxigenic Corynebacterium ulcerans. Int J Med Microbiol 2002 1.32
38 Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev 2008 1.26
39 CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 2014 1.19
40 Human bladder cancer diagnosis using Multiphoton microscopy. Proc SPIE Int Soc Opt Eng 2009 1.17
41 Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology 2012 1.16
42 Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. Chest 2012 1.15
43 ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 2010 1.14
44 Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol Biomarkers Prev 2008 1.13
45 Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Mod Pathol 2013 1.10
46 Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009 1.03
47 Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas. Diagn Mol Pathol 2011 1.01
48 Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biol 2015 1.01
49 Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol Histopathol 2013 0.98
50 Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer. Cancer Res 2009 0.97
51 The HOPE fixation technique--a promising alternative to common prostate cancer biobanking approaches. BMC Cancer 2011 0.97
52 Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn 2012 0.96
53 Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochem Pharmacol 2009 0.96
54 A case of sudden cardiac death due to isolated eosinophilic coronary arteritis. Chest 2005 0.94
55 In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. Am J Clin Pathol 2009 0.94
56 SOX2 expression and prognostic significance in ovarian carcinoma. Int J Gynecol Pathol 2013 0.93
57 GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". Am J Surg Pathol 2014 0.92
58 Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology 2011 0.90
59 Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology 2013 0.90
60 Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer 2011 0.89
61 Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer. Digestion 2013 0.89
62 Role of the NK cell-activating receptor CRACC in periodontitis. Infect Immun 2012 0.88
63 Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genet Cytogenet 2008 0.88
64 Exome enrichment and SOLiD sequencing of formalin fixed paraffin embedded (FFPE) prostate cancer tissue. Int J Mol Sci 2012 0.88
65 Activation of invariant NK T cells in periodontitis lesions. J Immunol 2013 0.85
66 The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key? Mol Med Rep 2011 0.85
67 Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer. Head Neck 2014 0.83
68 Prognostic significance of phospho-histone H3 in prostate carcinoma. World J Urol 2013 0.83
69 A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort. Appl Immunohistochem Mol Morphol 2014 0.83
70 Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression. Hum Pathol 2012 0.83
71 Sex determining region Y-box 2 (SOX2) amplification is an independent indicator of disease recurrence in sinonasal cancer. PLoS One 2013 0.82
72 MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer. Int J Cancer 2013 0.82
73 An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer. MAGMA 2008 0.82
74 Improved method of detecting the ERG gene rearrangement in prostate cancer using combined dual-color chromogenic and silver in situ hybridization. J Mol Diagn 2012 0.82
75 Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Br J Haematol 2015 0.81
76 Comparison of p40 (ΔNp63) and p63 expression in prostate tissues--which one is the superior diagnostic marker for basal cells? Histopathology 2013 0.81
77 In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival. Pigment Cell Melanoma Res 2014 0.81
78 α-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study. Prostate 2011 0.81
79 Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer. Pathology 2015 0.79
80 Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer. J Pathol 2013 0.79
81 ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer. Virchows Arch 2012 0.78
82 Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun 2015 0.78
83 Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis. World J Urol 2010 0.77
84 ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer. Int J Mol Med 2012 0.77
85 Analysis of receptor tyrosine kinase gene amplification on the example of FGFR1. Methods Mol Biol 2015 0.76
86 Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis. Blood 2013 0.76
87 Landscape of chromosome number changes in prostate cancer progression. World J Urol 2013 0.76
88 A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2008 0.75
89 A new bright-field dual-colour chromogenic and silver in situ hybridization method for the detection of FGFR1 gene copy number status. Virchows Arch 2014 0.75
90 Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells. Tumour Biol 2014 0.75
91 Palliative surgery for skeletal metastases from melanoma in the scaphoid--a critical case report appraisal. J Plast Reconstr Aesthet Surg 2012 0.75